The report sets out by saying that pregnant women all around the world are increasingly opting for non-invasive prenatal testing. It is particularly useful for detecting common fetal chromosomal aneuploidies, namely Down syndrome (trisomy 21), Edward’s syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X). Non-invasive prenatal testing is particularly useful in these cases since they are safe and accurate. Besides they are non-invasive unlike chorionic villus sampling (CVS) and amniocentesis.
The next-generation sequencing for non-invasive prenatal testing is being majorly fuelled by high incidence of children having Down syndrome. This, in turn, is because of increasing number of women planning to have kids much later in life. Apart from that, high risk of miscarriage too is promoting the market.
As per the findings of the Department of Biology in the University of Copenhagen, there are close to 7000 rare diseases occurring worldwide. Although they occur in one among 2000 people, they are major cause for concern since in most cases they do not have effective treatment. However, solid progress in the domain of next generation sequencing technology which can uncover new causative factors for such rare ailments has provided a ray of hope for patients. The innovative cell-free fetal DNA coupled with next generation sequencing, makes next-generation sequencing for non-invasive prenatal testing possible for rare diseases.
The only problem is that most of the currently-being-used genetic testing for rare diseases need gathering fetal samples via a process which is invasive. Those can cause maternal anxiety, sometimes leading to miscarriage. This has warranted development of a better method to carry out noninvasive prenatal test (NIPT) for rare diseases.
In order to study the next-generation sequencing for non-invasive prenatal testing market, the report segments it based on regions into Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. Among them, Europe is the largest market which is trailed by North America. Going forward, the market in North America is predicted to maintain its dominant position owing to high incidence of Down syndrome among children in the region. In Europe, the occurrence is even higher. In Asia Pacific, the market for next-generation sequencing for non-invasive prenatal testing has seen limited growth. This is because of the limited awareness about it in the region.
Obtain the Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14135
Some of the key players in the next generation sequencing for non-invasive prenatal testing market that have been profiled in the report are Agilent Technologies, Inc, Illumina, Inc., Biomatters, Ltd., Pacific Biosciences, BGI (Beijing Genomics Institute), Oxford Nanorpore Technologies, Ltd., Dnastar, Inc., and Life Technologies Corporation.